Navigation Links
Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
Date:5/3/2010

RYE, N.Y., May 3 /PRNewswire/ -- Dr. Joan Fallon, founder and CEO of Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, presented at the Keystone Symposia meeting, Toward Defining the Pathophysiology of Autistic Behavior, held in April in Snowbird, Utah.  

Fallon presented on "The Role of Protein Assimilation and Utilization in Children with Autism."  She discussed Curemark's research exploring a possible link between a lack of protein-digesting enzymes in autistic children, necessary for the production of amino acids needed for brain function, and the symptoms of autism.  

"The Keystone Symposia meeting provided an excellent forum to share our research with others in the scientific community who are attempting to understand the physiological causes of autism and working to develop possible therapies," Fallon said.

Curemark is in the midst of Phase III clinical trials for CM-AT, its autism treatment targeted as enzyme replacement therapy.  CM-AT recently was designated as a Fast Track drug by the FDA.

Keystone Symposia on Molecular and Cellular Biology is a non-profit organization with a 38-year history of organizing conferences to connect the scientific community and accelerate scientific discoveries.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
2. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
3. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
4. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Announces Senior Executive Promotions
7. Curemark CEO Presents at Epigenomics Conference
8. Curemark Closes Series A Financing
9. Curemark Appoints Preeminent Pediatrics Gastroenterologist
10. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
11. WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):